500 patients67,039 observations150 daysLIVE

Patient P-03159

Synthetic patientONX-7 · Day 143 · 35–44 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Favorable
GI state
Stable
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
58%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S14
  2. Day 39 NP-02 recommendedDietary Support Protocol NP-02
  3. Day 40 Patient acceptedStarted NP-02 in the companion
  4. Day 50 GI symptom burden −19% vs expectedDietary Support Protocol NP-02
  5. Day 56 Tolerance state changedUnstable → Improving
  6. Day 67 Trajectory diverged from predictionObserved response fell below the model's expected path.
  7. Day 67 GI-04 recommendedGI Support Protocol GI-04
  8. Day 68 Patient acceptedStarted GI-04 in the companion
  9. Day 76 GI symptom burden −31% vs expectedGI Support Protocol GI-04
  10. Day 82 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 67.

Primary contributors, last 14 days
  • Toxicity-3
  • GI instability-2

What helped?

  • Dietary Support Protocol NP-02Day 39
    Result: symptom burden −19%
  • GI Support Protocol GI-04Day 67
    Result: symptom burden −31%
LIFE OS recommendation
Clinician Review CR-01
74%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 100% showed improvement
  • median effect visible after 5 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Energy level
Daily log
2.7/10
stable · +0.1 vs previous 14 d
Stress level
Daily log
6.2/10
stable · -0.2 vs previous 14 d
Pessimism score
Daily log
5.6/10
stable · -0.0 vs previous 14 d
Sleep quality
Wearable
14/100
worsening · -1.8 vs previous 14 d
Libido
Daily log
3.5/10
improving · +0.4 vs previous 14 d
HRV
Wearable
25 ms
worsening · -2.1 vs previous 14 d
Toxicity
Blood
33.7/100
improving · -2.7 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 33 from the failing basin, 56 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 11 similar · onset 3 d · confidence 62%
  • DT-01 Dosing / Timing Recommendation
    63% improved among 8 similar · onset 5 d · confidence 62%
  • CR-01 Clinician Review
    100% improved among 5 similar · onset 5 d · confidence 62%
  • More protein
    GI -7.3 next day on high-intake days · n 17
Would not help
  • AD-05 Adherence Support
    only 25% improved among 12 similar
  • Keep fat low
    GI +5.9 next day on high-intake days · n 23
  • Keep lactose low
    GI +5.3 next day on high-intake days · n 23
  • Keep histamine low
    GI +5.2 next day on high-intake days · n 23
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Protein
    -7.3supporter · 95%
  • Dietary fat load
    +5.9detractor · 95%
  • Lactose
    +5.3detractor · 95%
  • Histamine load
    +5.2detractor · 95%
  • Alcohol
    +0.4no signal · 15%
  • Caffeine
    0no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 70
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • WearableSleep 5.2 h, below personal baseline
  • Inflammatory signalling 60
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 48
    • WearableHRV 25 ms, trending down
  • Butyrate / short-chain fatty acid production 60
    • MicrobiomeButyrate capacity 42/100
    • MicrobiomeF. prausnitzii depleted
  • Autonomic recovery 45
    • WearableResting HR 80 bpm
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • CYP2D6 Intermediate metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.5 · butyrate capacity 42/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
24 ms
Sleep
5.7 h
Steps
4,870
Resting HR
78 bpm
Daily log: GI score 45, nutritional resilience 51, adherence 51.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0322650%S05GI-04improved43
P-0330046%S14GI-04improved46
P-0309044%S02GI-04improved48
P-0314540%S14GI-04improved51
P-0312338%S14GI-04improved50
P-0307037%S14GI-04improved51
P-0343037%S14SC-12improved45
P-0303736%S14NP-02improved43
P-0304936%S14GI-04improved49
P-0314636%S14GI-04improved53
P-0322536%S19GI-04improved50
P-0300335%S08SC-12improved53